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Retroviral vectors efficiently insert exogenous genes into a wide range of human cells and have been extensively studied in an attempt to develop gene therapy protocols. 1, 2 Although gene transfer is generally successful, high level, long-term expression in primary cells is problematic. One of the major drawbacks is in vitro and in vivo inhibition of transgene expression because of DNA methylation. 3, 4 The DNA demethylating agent 5′ azacytidine (aza-C) is reported to reactivate transgene expression. 5, 6 We report inhibition of transgene expression occurs in the stably infected U937 human cell line in vitro and in vivo and aza-C treatment prevents DNA methylation. We used a bicistronic retroviral vector to transduce the U937 human cell line. Through an internal ribosome entry site (IRES) 7 sequence the vector cotransfers the herpes simplex virus type 1 thymidine kinase gene (HSVtk), which induces sensitivity to ganciclovir (gcv), and a marker gene, the bacterial beta-galactosidase gene (lacZ) (Figure 1a) . By injecting the HSVtk/lacZ transduced U937 cells in mice with severe combined immunodeficient disease (SCID), we generated a tumor which, when the animal was killed, was almost completely methylated. In vivo treatment with aza-C prevented transgene methylation, as demonstrated by increased lacZ expression and gcv sensitivity. When aza-C was combined with gcv, tumor onset was significantly delayed. Our study shows aza-C prevents DNA methylation. This may have implications for gene therapy in genetic and neoplastic diseases.
As previously reported, 8 by transferring MFG/tk-IRESlacZ into the GP+envAM12 cell line, we obtained an amphotropic producing cell line capable of infecting U937 cells by co-cultivation. After enrichment of the transduced cells by cell sorting, 9 end-point dilution was performed. The procedure yielded clones expressing lacZ heterogenously (range 0-90%). Only the lacZ-positive clones were sensitive to gcv. Expression of the two genes closely correlated because of the IRES sequence. In the lacZ-negative/ganciclovir-resistant clones the transgene was integrated but not expressed. Two clones with extreme phenotypes, VB51 (containing 0% lacZ-expressing cells) and VB71 (Ͻ90% of the cells lacZ-positive) were used for further studies.
Long-term analysis of lacZ gene expression in the VB71 clone showed the percentage of lacZ-positive cells remained stable for 1 month and then fell significantly to about 2% after 2 months culture. Treatment of the population containing 2% of lacZ-positive cells with aza-C for 3 days raised the percentage of lacZ positive cells to baseline values (approximately 90% of blue cells), indicating the decrease in lacZ-positive cells was associated with DNA hypermethylation (Figure 1b ). Aza-C had no effect on the VB51 clone. Morphological analysis and immunophenotying with monoclonal antibodies against myelomonocytic antigens showed aza-C, at the dosage used, had no differentiation effect on U937 clones. In order to assess the effects of methylation on transgene expression in vivo, we inoculated SCID mice intraperitoneally with the VB71 cell line and with VB71 associated with gcv 16 GP+envAM 12 cells and derivatives, 17 and/or aza-C. No blood or organ toxicity was observed with either gcv or aza-C at the administered dosage. Tumours developed at a mean of 29.3 days (range 28-37) after VB71 injection (controls, group I); after a mean of 31.6 days (range 17-45) in group II, treated with aza-C alone; after a mean of 36.8 days (range 28-50) in group III treated with gcv alone; and after a mean of 74.6 days (range 64-95) in group IV, treated with gcv and aza-C (Figure 2 ). Tumour onset was significantly delayed in mice treated with gcv compared with controls (P = 0.01). The delay in tumour onset was significantly longer when animals were treated with both gcv and aza-C (P Ͻ 0.0001) versus mice treated with gcv alone or with aza-C alone. LacZ expression in the tumour masses after death was weak (1-2% lacZ-positive cells) in group I, which was maintained at 80-90% in group II (Figure 3) . No lacZ-positive cells were found in groups III and IV. Because of transgene hypermethylation in group III and the demethylating effect of aza-C in group IV both groups were completely lacZ-negative and resistant to gcv. Aza-C treatment of tumour-derived cells from groups III and IV showed transgene expression was reactivated in group III (as shown by lacZ positivity and gcv response), but not in group IV (as shown by lacZ negativity and gcv resistance). Tumour onset in group IV was due to the U937 cell line with the integrated but not expressed transgene (about 10% of injected cells) (Figure 1c) . We also analysed the effect of aza-C and gcv on the growth of tumours derived from unmodified U937 cells. The same schedule of cell injection and drug administration was adopted (four groups of mice Ia, IIa, IIIa, IVa). No significant difference was found in tumour growth in the four groups, even when compared with the tumour onset time in the controls.
Figure 1 (a) Map of MFG/tk-IRES-lacZ vector. This vector derives from a MFG retroviral backbone in which the HSVtk and E. coli lacZ genes were linked by an IRES sequence. GP+E86 cells and derivatives,
Provirus methylation analysis by Southern blot was performed as reported elsewhere. 4, 5 SmaI is a methylation-sensitive enzyme that can cleave DNA at the CCCGGG site only if the CpG sequence is not methylated; therefore, SmaI resistance was used as a measurement of DNA methylation. NcoI/HindIII digested chromosomal DNA from tumour-derived cells was digested with SmaI. The blot was hybridized with the 5′LTR-specific probe. In the VB71 cell line Southern blot showed a single hybridising fragment after NcoI/HindIII digestion (Figure 4 lane 1) . Lane 2 showed the hybridised fragments found after SmaI digestion of the VB71 cell II, for group for group IV. P = 0.01 for group I versus group III; P Ͻ 0.0001 for group I versus group IV; P Ͻ 0.0001 for group II versus group IV; P Ͻ 0.0001 for group III versus group IV).
cells; group II with cells followed by aza-C (2 mg/kg every 48 h until tumour onset); group III cells followed by gcv (10 mg/kg from day +1) until the onset of tumour; group IV cells + aza-C as in group II + gcv as in group III. Treated animals were injected at ages 35 days (n = 9 for each group) with a single intraperitoneal dose of VB71 cells (group I), followed by aza-C (group II), gcv (group III) and aza-C + gcv (group IV). Mean tumour onset was after 29.3 (28-37) days for group I, 31.6 (17-45) for group

Figure 3 Cytochemical staining to assess ␤-galactosidase activity on imprints of tumour cells when animals were killed. (a) Group I: few, light coloured lacZ-positive cells (magnification ×200); (b) group II: darker staining of tumour cells (magnification ×100) (upper right magnification ×400); (c) groups III-IV: no staining of tumour masses (magnification ×200). To reveal lacZ activity in situ, cells were fixed and stained with 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal) (Sigma) 2 days after infection.
19 Cells were incubated overnight in the staining solution before counting the lacZpositive cells. Our results demonstrate that expression of retrovirally transduced genes, may be kept stable by administering aza-C, which prevents hypermethylation and guarantees high level expression of the retroviral construct both in vitro and in vivo.
It has long been known that transgene methylation frequently inhibits transgene expression 10, 11 and that in the long terminal repeat (LTR) of the Moloney murine leukaemia virus (MoMuLV) the enhancer sequences are targets for de novo methylation of CpG residues.
12, 13 The role of aza-C in reactivating methylated sequences has been studied in different tumour cell lines, but results are conflicting. Hoeben et al 5 reported aza-C reactivated methylated gene in vitro but Chen et al 14 observed no reactivated expression in HeLa cells infected with recombinant adeno-associated virus (rAAV) containing a CMV/lacZ. These discrepancies are probably due to the different vectors they used. Vectors derived from the MoMuLV meth- ylate more easily than adenoviral vectors in which hypoacetylation of histones might be involved in the silencing of virally transduced genes. Jaenisch et al 6 demonstrated that in vivo treatment with aza-C efficiently reactivated premethylated proviruses carrying a mutation in the coding regions which implied high methylation and biological inactivity. Our results show that it is possible not only to reactivate a construct silencing because of DNA methylation, but also to prevent methylation in vivo by continuous aza-C administration.
Because most experimental and clinical protocols use the MoMuLV-derived vector, these results have important implications for the use of retroviral vectors in gene therapy trials. Previous clinical use of aza-C, 15 administered at 2 mg/kg body weight per day by continuous intravenous infusion for 4 days at 2-to 4-week intervals, has produced long-term therapeutic benefits in patients with end-stage ␤-thalassemia. The only direct side effect of aza-C was a dose-dependent neutropenia, which was compensated by reducing the size or frequency of the aza-C dose. As aza-C is well tolerated in vivo under experimental conditions (as our results show) and in humans, 15 it might be a valid way of overcoming methylation and promoting stable gene expression and long-term benefits.
